Summary
85 / 100 · Bulios Score
What speaks for it
- Out of every 100 CNY of revenue, 73 CNY is left as net profit.
- Revenue grew by 60% a year over the last 3 years.
- It earns 56 CNY a year on every 100 CNY of invested capital.
- It holds more cash than debt: ¥1.55B against ¥311.0M.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 6.5 CNY for 1 CNY of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (CNY)
Diluted EPS (CNY)
- Analyst estimate
Revenue grew by 60% a year over the last 3 years. For the next fiscal year analysts expect revenue to grow by 143%.
Growth in detailDoes it make money?
Very wellWhere 100 CNY of revenue goes
- Cost of sales 7.3 CNY
- Research and development 8.5 CNY
- Sales and administration 23 CNY
- Taxes and other -12 CNY
- Net profit 73 CNY
Net profit, industry median (Biotechnology) -7.3 CNY
Out of every 100 CNY of revenue, 73 CNY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.